ArrowMark Colorado Holdings LLC Lowers Holdings in AxoGen, Inc. (NASDAQ:AXGN)

ArrowMark Colorado Holdings LLC decreased its position in shares of AxoGen, Inc. (NASDAQ:AXGN) by 55.5% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,275,463 shares of the medical equipment provider’s stock after selling 2,841,088 shares during the quarter. ArrowMark Colorado Holdings LLC owned 0.05% of AxoGen worth $31,902,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in AXGN. First Light Asset Management LLC grew its position in shares of AxoGen by 336.6% during the 2nd quarter. First Light Asset Management LLC now owns 3,344,033 shares of the medical equipment provider’s stock valued at $24,211,000 after acquiring an additional 2,578,147 shares during the period. Assenagon Asset Management S.A. increased its position in shares of AxoGen by 2,014.6% in the second quarter. Assenagon Asset Management S.A. now owns 1,310,811 shares of the medical equipment provider’s stock valued at $9,490,000 after buying an additional 1,248,823 shares in the last quarter. Divisadero Street Capital Management LP raised its stake in shares of AxoGen by 587.2% during the 2nd quarter. Divisadero Street Capital Management LP now owns 686,994 shares of the medical equipment provider’s stock worth $4,974,000 after buying an additional 587,024 shares during the period. Charles Schwab Investment Management Inc. lifted its position in shares of AxoGen by 8.6% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 363,764 shares of the medical equipment provider’s stock valued at $5,100,000 after buying an additional 28,659 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. grew its stake in AxoGen by 66.3% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 308,686 shares of the medical equipment provider’s stock valued at $4,328,000 after acquiring an additional 123,118 shares during the period. Hedge funds and other institutional investors own 80.29% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have weighed in on AXGN shares. JMP Securities upped their price objective on shares of AxoGen from $17.00 to $20.00 and gave the stock a “market outperform” rating in a research report on Friday, August 9th. StockNews.com upgraded AxoGen from a “hold” rating to a “buy” rating in a report on Tuesday, October 15th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, AxoGen currently has a consensus rating of “Buy” and a consensus price target of $15.00.

AxoGen Price Performance

Shares of NASDAQ AXGN opened at $13.90 on Monday. The firm has a 50-day simple moving average of $13.68 and a 200-day simple moving average of $10.88. The company has a quick ratio of 2.47, a current ratio of 3.74 and a debt-to-equity ratio of 0.67. The stock has a market capitalization of $611.74 million, a price-to-earnings ratio of -43.44 and a beta of 1.13. AxoGen, Inc. has a 52 week low of $5.55 and a 52 week high of $15.90.

AxoGen Profile

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.